OSI-906 (Linsitinib)

OSI-906 (Linsitinib) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.

Price Stock Quantity  
USD 190 In stock
USD 170 In stock
USD 270 In stock
USD 720 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

OSI-906 (Linsitinib) Chemical Structure

OSI-906 (Linsitinib) Chemical Structure
Molecular Weight: 421.49

Validation & Quality Control

Customer Product Validation(3)

Quality Control & MSDS

Related Compound Libraries

IGF-1R Inhibitors with Unique Features

  • Pan IGF-1R Inhibitor

    GSK1904529A Dual IGF-1R/IR inhibitor, IC50=27 nM/25 nM.

  • Most Potent IGF-1R Inhibitor

    BMS-754807 IGF-1R, IC50=1.8 nM; InsR, IC50=1.7 nM.

  • IGF-1R Inhibitor in Clinical Trial

    BMS-754807 Phase II for Breast Cancer.

  • Newest IGF-1R Inhibitor

    PQ 401 Inhibitor of autophosphorylation of IGF-1R domain with IC50 of <1 μM.

Product Information

  • Compare IGF-1R Inhibitors
    Compare IGF-1R Products
  • Research Area
  • Inhibition Profile

Product Description

Biological Activity

Description OSI-906 (Linsitinib) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.
Targets IGF-1R [1]
(Cell-free assay)
Insulin Receptor [1]
(Cell-free assay)
IRR [1]
(Cell-free assay)
Abl [1]
(Cell-free assay)

 View  More

IC50 35 nM 75 nM 75 nM >10 μM
In vitro OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. [1]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
A4-FukMUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmnETWM2OD1yLkCyPFA3KM7:TR?=M1fqNnNCVkeHUh?=
KS-1NGG2RW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXPJR|UxRTBwMEO4N|Uh|ryPNXOxV2I3W0GQR1XS
TE-11NGGxPFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX3JR|UxRTBwMEe4NlIh|ryPNHryd4hUSU6JRWK=
EW-1NWPE[FBsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV7JR|UxRTBwMEi1PFUh|ryPNGDZV|VUSU6JRWK=
HMV-IINXnPNGQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFj2NY9KSzVyPUCuNFg5PDZizszNM13BVHNCVkeHUh?=
COLO-205MkLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoXKTWM2OD1yLkGwOFU1KM7:TR?=MkHkV2FPT0WU
ES1Mn70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4mwS2lEPTB;MD6xNFY6PiEQvF2=M3Po[3NCVkeHUh?=
GDM-1MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn;jTWM2OD1yLkGzOlczKM7:TR?=NWLleVZzW0GQR1XS
ML-2MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEfYc4pKSzVyPUCuNVU5QTZizszNNHHpXY5USU6JRWK=
Saos-2MmPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYm5SGViUUN3ME2wMlE3PTJ4IN88US=>MoP2V2FPT0WU
NCI-H1355M3;p[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml7KTWM2OD1yLkG4NVM2KM7:TR?=MnHzV2FPT0WU
G-401MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlLFTWM2OD1yLkG4NlMh|ryPM{DJdXNCVkeHUh?=
EW-16MnTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXXJR|UxRTBwMUi3O|ch|ryPM{PxPXNCVkeHUh?=
EW-7M2jB[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWPJR|UxRTBwMUi4PFEh|ryPNVTz[W8zW0GQR1XS
NCI-H727MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFrnelNKSzVyPUCuNVk4QTRizszNNF;jeohUSU6JRWK=
LCLC-97TM1MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXTJR|UxRTBwMkC5OVUh|ryPMmXNV2FPT0WU
NCI-H650MknoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkOyTWM2OD1yLkKxN|g1KM7:TR?=NF3sWldUSU6JRWK=
NCI-H2122MoC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGPpU4lKSzVyPUCuNlMzQTlizszNNV74[YNvW0GQR1XS
SK-N-DZNY[3OlNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHH3S|dKSzVyPUCuNlM3QThizszNNYPTTJN3W0GQR1XS
HT-29NHnwZlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYPTZ4Y5UUN3ME2wMlI1OjR6IN88US=>Mnn0V2FPT0WU
LB771-HNCNUD0d3NST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1zJWGlEPTB;MD6yOVkyPSEQvF2=NX71cFdQW0GQR1XS
HT-144M1XRdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlP1TWM2OD1yLkK2NVkyKM7:TR?=NFOzWmVUSU6JRWK=
LAN-6MkDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWDJR|UxRTBwMk[zOFgh|ryPMXXTRW5ITVJ?
EW-18NHGxXmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHHnRYlKSzVyPUCuNlcxODFizszNNYTuPWVNW0GQR1XS
LS-1034MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkDKTWM2OD1yLkK3NVMzKM7:TR?=Mlv5V2FPT0WU
EW-11MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MofRTWM2OD1yLkK4OFMzKM7:TR?=M{PORXNCVkeHUh?=
SNU-C1M{KydGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFXHXFZKSzVyPUCuNlk{OTNizszNM{mx[HNCVkeHUh?=
RS4-11MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIKwS5lKSzVyPUCuN|M4PThizszNNU\UZ5Z2W0GQR1XS
ES4NF\YbYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkHCTWM2OD1yLkSxNFM5KM7:TR?=M3zxOXNCVkeHUh?=
COLO-320-HSRM1XH[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYm5TW9vUUN3ME2wMlQyOzZ6IN88US=>MnG1V2FPT0WU
NB10MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MofXTWM2OD1yLkS1OFM4KM7:TR?=NYPuSVV4W0GQR1XS
BFTC-905M1zLUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWTJR|UxRTBwNE[3OVgh|ryPM2S3ZnNCVkeHUh?=
A375M4XYdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGHz[2pKSzVyPUCuOFc3OTdizszNNIL5WHNUSU6JRWK=
SJRH30MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4LHO2lEPTB;MD61NFgzOiEQvF2=NWDrTFM5W0GQR1XS
NOS-1MkL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3nETWlEPTB;MD61NlI3PyEQvF2=Mn;mV2FPT0WU
SIG-M5NH3iWFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX\YOXM4UUN3ME2wMlU{PTV5IN88US=>NF72OnlUSU6JRWK=
DOKNWHJcphpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mm\3TWM2OD1yLkW1OkDPxE1?M3LMTnNCVkeHUh?=
NB69NInJWY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFTaUI1KSzVyPUCuOVgzPTdizszNM2HJc3NCVkeHUh?=
SK-NEP-1MnPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXrJR|UxRTBwNkCyN|Yh|ryPMYTTRW5ITVJ?
SK-MM-2MmfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHzXNVVKSzVyPUCuOlU1QTFizszNMV7TRW5ITVJ?
NCI-H358MljpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXjJR|UxRTBwNkewPFIh|ryPM4jjO3NCVkeHUh?=
RH-1MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1XU[GlEPTB;MD63OFg2QSEQvF2=NVLR[IU6W0GQR1XS
NH-12M17IU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVjVWmZoUUN3ME2wMlc3ODR4IN88US=>NUjDOVE3W0GQR1XS
TE-12Mn7sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MknmTWM2OD1yLke2OFg3KM7:TR?=MUXTRW5ITVJ?
COLO-668NVjVd|d[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXXJR|UxRTBwOES2OlYh|ryPNXvMN5F2W0GQR1XS
PANC-08-13MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYrrfFY3UUN3ME2wMlg3Ozd5IN88US=>MUXTRW5ITVJ?
HCC2998NIHsVJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYfJR|UxRTBwOEiyOlMh|ryPMWXTRW5ITVJ?
ABC-1NYDKTZQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4H2e2lEPTB;MD65NFM2OiEQvF2=NXHyPZRbW0GQR1XS
ES6NYfZ[2tPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlH6TWM2OD1yLkmxNFY3KM7:TR?=NGfNbphUSU6JRWK=
SNU-387NEXHV3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1u2TGlEPTB;MD65PVM6OyEQvF2=NFTi[o5USU6JRWK=
CMKMo[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mlz6TWM2OD1yLkm5PVI6KM7:TR?=NGXDSYxUSU6JRWK=
SJSA-1MnO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXTJR|UxRTFwMEO2OVMh|ryPMkLhV2FPT0WU
SIMANUD6dZBET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{TJ[mlEPTB;MT6wOlgzPSEQvF2=MkfKV2FPT0WU
ES3NXnpU41rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHvYbpFKSzVyPUGuNVIzQTdizszNNEPkfohUSU6JRWK=
IGROV-1M322U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXPJR|UxRTFwMUW0OFQh|ryPNWTlTIdRW0GQR1XS
MEL-JUSOM{eye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnHrTWM2OD1zLkG1O|U6KM7:TR?=NVHPNplQW0GQR1XS
T84NEL4[FNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnHnTWM2OD1zLkKwPVE1KM7:TR?=NGm3NopUSU6JRWK=
CAL-85-1NFHLSFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2GwemlEPTB;MT6yN|E{QCEQvF2=M37oPXNCVkeHUh?=
RDMoqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3HYTGlEPTB;MT6yOlQ2PSEQvF2=MXPTRW5ITVJ?
TE-8NXnkOZlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{L4NWlEPTB;MT6zNVQ3OiEQvF2=NEnlcldUSU6JRWK=
L-363MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mo\xTWM2OD1zLkO0NlA5KM7:TR?=M3PjWHNCVkeHUh?=
EKVXMWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3jLcmlEPTB;MT6zOFU3QCEQvF2=NVe0Z5g1W0GQR1XS
SK-MEL-3NHXKUZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MonrTWM2OD1zLkS4OVU3KM7:TR?=M4jGN3NCVkeHUh?=
TGBC24TKBM3fVc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYrweG5mUUN3ME2xMlUxOTl|IN88US=>MVPTRW5ITVJ?
NCI-H1770NX:4bmlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWHJR|UxRTFwNUGxNVMh|ryPMn3iV2FPT0WU
HuH-7MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3\2V2lEPTB;MT62NFA6QCEQvF2=M2PoR3NCVkeHUh?=
HL-60MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX\2TJpUUUN3ME2xMlY3QTJ6IN88US=>NUnISo93W0GQR1XS
TE-1Mkj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1XRdmlEPTB;MT63NFk1PSEQvF2=Mkf1V2FPT0WU
LC-2-adM1PjRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX\MflR7UUN3ME2xMlc{QDh5IN88US=>MVHTRW5ITVJ?
LB647-SCLCNHfIOFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYfX[JdJUUN3ME2xMlc3PTh|IN88US=>M2LSeHNCVkeHUh?=
NCI-H2171Mn:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWrJR|UxRTFwN{e3NVYh|ryPNVGzPYdYW0GQR1XS
SK-PN-DWM4na[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVzJR|UxRTFwOUGyPVgh|ryPNEH3UFlUSU6JRWK=
MC-IXCMmrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkjkTWM2OD1zLkm4PVgh|ryPM1TydnNCVkeHUh?=
LS-513MnjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWHJR|UxRTJwMEWzNFUh|ryPNYXT[4VyW0GQR1XS
EW-3NEfJe4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Moi5TWM2OD1{LkC5PFQ1KM7:TR?=NY\DdoJEW0GQR1XS
OPM-2NGPoOnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX36NHk{UUN3ME2yMlExOiEQvF2=NVqybnJCW0GQR1XS
LP-1Ml;uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4DGfmlEPTB;Mj6yOVgxPyEQvF2=NW\Fc5NnW0GQR1XS
LU-134-ANHvQ[YlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYS3clJyUUN3ME2yMlI4PyEQvF2=NGTIOGlUSU6JRWK=
CP66-MELNXHRb|BjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXLJR|UxRTJwMkmwNVQh|ryPMUHTRW5ITVJ?
HCC1143NEXuV3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmrsTWM2OD1{LkS1N|Y5KM7:TR?=NUDxblNVW0GQR1XS
LOXIMVIMYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnTETWM2OD1{Lk[wNlEh|ryPNHLRUYtUSU6JRWK=
TE-10MnXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEnXe2NKSzVyPUKuO|A5OzhizszNMonZV2FPT0WU
NCI-H1882MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH\mXZNKSzVyPUKuO|UzOjdizszNMnPIV2FPT0WU
CHP-126NH\mXndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUPJR|UxRTJwN{[zNVch|ryPMl\JV2FPT0WU
NCI-H1623M1zve2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUnlZ283UUN3ME2yMlkzODJ2IN88US=>NF\4WXhUSU6JRWK=
GB-1MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NY\hUpFIUUN3ME2yMlk{PDB2IN88US=>MXnTRW5ITVJ?
RCC10RGBMXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUW2bZcxUUN3ME2yMlk2OjhzIN88US=>NHi2W2pUSU6JRWK=
NCI-H2141M{Prdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2HWTWlEPTB;Mj65Olg6PiEQvF2=MkizV2FPT0WU
GI-ME-NNYjJWpFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mnn3TWM2OD1|LkCwOVY2KM7:TR?=MY\TRW5ITVJ?
NCI-H526NVHvfZozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIHnWWlKSzVyPUOuNFQxQDVizszNM2rueXNCVkeHUh?=
NCI-H747M37KWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUnJR|UxRTNwMES5PVIh|ryPM4S1THNCVkeHUh?=
SNU-423MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnjYTWM2OD1|LkKwN|E{KM7:TR?=M3zCUXNCVkeHUh?=
A427NXHqUGxiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml3pTWM2OD1|LkK1Olk6KM7:TR?=M1X2SXNCVkeHUh?=
CAL-12TMkDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlvYTWM2OD1|LkSwO|E{KM7:TR?=NXHkdIJCW0GQR1XS
LU-99ANUXXb|VuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX\JR|UxRTNwNEexNFUh|ryPNHPpbmxUSU6JRWK=
MS-1NYHwXIFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmfaTWM2OD1|LkWzOFI6KM7:TR?=NXXvdXhNW0GQR1XS
SK-LU-1MorCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXLMb|RGUUN3ME2zMlc3Ojl3IN88US=>M1TObXNCVkeHUh?=
SW837NXT2SWVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV7JR|UxRTNwN{[zN|Mh|ryPM{P3bHNCVkeHUh?=
ES8NITM[llIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnfrTWM2OD1|LkizPFc4KM7:TR?=NVizeYd7W0GQR1XS
MZ2-MELNGPESWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVPSN4VEUUN3ME2zMlkzODh4IN88US=>NInPfpVUSU6JRWK=
TGWMn3VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnnOTWM2OD12LkCxN|EyKM7:TR?=NI\peXZUSU6JRWK=
GP5dNWPOSlc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3W3TWlEPTB;ND6wOVM3OiEQvF2=MknmV2FPT0WU
BB49-HNCM{j0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mk\TTWM2OD12LkG1NlE{KM7:TR?=M4DRfHNCVkeHUh?=
NB13NHXiSIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIP3e3VKSzVyPUSuNlY5QDdizszNNUP4V5hTW0GQR1XS
NTERA-S-cl-D1MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYLoSJpXUUN3ME20MlI5PjF3IN88US=>MW\TRW5ITVJ?
NCI-H1648NUjF[HJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2PwXWlEPTB;ND6yPVgyQSEQvF2=NHHLeJlUSU6JRWK=
LCLC-103HMV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIr2TXhKSzVyPUSuN|IyQTVizszNMnnwV2FPT0WU
LS-411NMUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHy0T3RKSzVyPUSuOFQ5QDVizszNMXXTRW5ITVJ?
NCI-H1092MlfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{TnSWlEPTB;ND60OVY5PyEQvF2=NX62R21kW0GQR1XS
PANC-10-05M1nMZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2jGZ2lEPTB;ND62PVg1KM7:TR?=Mn\GV2FPT0WU
DK-MGMWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkfhTWM2OD12LkiwPVM{KM7:TR?=M3\GUHNCVkeHUh?=
OVCAR-5NHv6WFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4XvWWlEPTB;ND64NVIzPiEQvF2=NIi3fIJUSU6JRWK=
CAL-39NXnSUmdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml7hTWM2OD12Lki3Olch|ryPMX3TRW5ITVJ?
TE-441-TMnXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4\ab2lEPTB;ND65NFU{PyEQvF2=M1i3S3NCVkeHUh?=
MOLT-16MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXHTUmhwUUN3ME20Mlk2OjV|IN88US=>NWDEVZdxW0GQR1XS
MCF7M1;4eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1vtd2lEPTB;NT6xOFUyPyEQvF2=MXXTRW5ITVJ?
CAPAN-1M4jNNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHPBN3pKSzVyPUWuNlU4ODdizszNM2OwWXNCVkeHUh?=
PSN1MoruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX[5cnh3UUN3ME21MlI4OjN3IN88US=>M2j6[nNCVkeHUh?=
NCI-H292MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWrJR|UxRTVwM{CwOFQh|ryPMVPTRW5ITVJ?
CPC-NMmPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmfYTWM2OD13LkO5OFE6KM7:TR?=M1q0Z3NCVkeHUh?=
DoTc2-4510NHTiTo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX\JR|UxRTVwNEWzO|Eh|ryPMn7sV2FPT0WU
LB1047-RCCMnf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH;NNFRKSzVyPUWuOVU6OzNizszNMmL2V2FPT0WU
MHH-ES-1NHTyR3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV\lS|FoUUN3ME21MlU6QTB5IN88US=>NX\mXpIyW0GQR1XS
NMC-G1MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWXJR|UxRTVwN{CyNlch|ryPM2nsRnNCVkeHUh?=
SW1710NG\zVppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVXhNWQyUUN3ME21Mlc1PzVzIN88US=>MULTRW5ITVJ?
YAPCMXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnH0TWM2OD13Lke2NlAyKM7:TR?=NHG4XoxUSU6JRWK=
22RV1M2eydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3P1U2lEPTB;NT64NFAyQSEQvF2=MUfTRW5ITVJ?
COLO-679MlTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2jnSWlEPTB;NT64PFk1QCEQvF2=MXTTRW5ITVJ?
TCCSUPMn7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlryTWM2OD13LkmzNlU6KM7:TR?=NXfLRWtLW0GQR1XS
C2BBe1NVK0N2xLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkXLTWM2OD13LkmzPVch|ryPMXTTRW5ITVJ?
TE-15NFO0NYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2OyOWlEPTB;Nj6wOlYxPSEQvF2=MkDjV2FPT0WU
SCLC-21HMlHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoDVTWM2OD14LkGwPFQ{KM7:TR?=NWOxcHVoW0GQR1XS
EoL-1-cellMmr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3nET2lEPTB;Nj6xOlU3OyEQvF2=NH;1RphUSU6JRWK=
NKM-1NGXlVGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGHnXpZKSzVyPU[uNVY4OSEQvF2=NWDLNoNIW0GQR1XS
NCI-H1304M1OyVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYfJR|UxRTZwMke0Nlgh|ryPMkDsV2FPT0WU
NB6MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWLOdolQUUN3ME22MlI6PjJ{IN88US=>NWHIN4xUW0GQR1XS
NALM-6MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVrJR|UxRTZwM{OyN{DPxE1?M1vj[XNCVkeHUh?=
NCI-H522MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWD0W4hUUUN3ME22MlM{OzB4IN88US=>M4D3ZnNCVkeHUh?=
MV-4-11MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1Pa[2lEPTB;Nj6zO|A4QSEQvF2=NFSzSFZUSU6JRWK=
LB2241-RCCMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXjLVpQ2UUN3ME22MlM5PjZ5IN88US=>MVHTRW5ITVJ?
NCI-H1417MlPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NED0cm9KSzVyPU[uOFA5PDdizszNMWfTRW5ITVJ?
HT-1197NFTPU|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4PkXGlEPTB;Nj61O|EzOiEQvF2=M4KxRXNCVkeHUh?=
P30-OHKM3jQUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlLKTWM2OD14Lk[yO|ch|ryPNVrTUWVEW0GQR1XS
ALL-PONEHDSYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlnXTWM2OD14LkexPVE3KM7:TR?=MkPiV2FPT0WU
OVCAR-4MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1;aZWlEPTB;Nj63OVQxPSEQvF2=NVHiXmpQW0GQR1XS
HCC2157M1PZfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWDkb4Y2UUN3ME22Mlc4PDd3IN88US=>NInjZXBUSU6JRWK=
NCI-H838Mnf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIPt[lJKSzVyPU[uPVY1QSEQvF2=MWHTRW5ITVJ?
NCI-H1299MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoHaTWM2OD14Lkm3NFkh|ryPNYTJcXdqW0GQR1XS
SW954MoW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWnJR|UxRTdwMkCwOlgh|ryPMYrTRW5ITVJ?
NCI-H441NHnCUpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVvJR|UxRTdwM{SwOlUh|ryPMki1V2FPT0WU
SK-MEL-2NVKxS2hDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{S3SmlEPTB;Nz60PFM4OyEQvF2=MXXTRW5ITVJ?
KARPAS-45NYjTSplkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{n5ZmlEPTB;Nz62OVkzQSEQvF2=NUjOcG9tW0GQR1XS
CAL-54NUC1flNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXLJR|UxRTdwOEK5O|ch|ryPM4rB[HNCVkeHUh?=
KYSE-180MnHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYr6R5dKUUN3ME23Mlg5QTRzIN88US=>MWfTRW5ITVJ?
NCI-H187MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXu1boc1UUN3ME23Mlk2QTR5IN88US=>M3WyTnNCVkeHUh?=
RT-112MojnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnH3TWM2OD16LkC5Olc4KM7:TR?=NIDoeZNUSU6JRWK=
NCI-H1437M2SwTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn\qTWM2OD16LkC5O|k2KM7:TR?=NEX6VnBUSU6JRWK=
SNU-449NGnPWJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NW\MbZg6UUN3ME24MlI5Ojd{IN88US=>MYnTRW5ITVJ?
HCC1187M3HY[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX[xToNQUUN3ME24MlI6OzlzIN88US=>NITjdHNUSU6JRWK=
NCI-H2030NFGzVFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M17DRWlEPTB;OD6zO|cyPCEQvF2=NWr2SJl6W0GQR1XS
HuO-3N1MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV7uTHBNUUN3ME24MlM4QDR2IN88US=>M4P2VHNCVkeHUh?=
COLO-792NIi5NGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1XWbGlEPTB;OD60NVUzPyEQvF2=MWrTRW5ITVJ?
MIA-PaCa-2MoT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVTJR|UxRThwOEW1NFgh|ryPMmDJV2FPT0WU
SK-N-FIM{LjZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkS2TWM2OD17LkC0NlUh|ryPMn3lV2FPT0WU
MMAC-SFM1vUZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MorBTWM2OD17LkC5O|UyKM7:TR?=NVK0bnU4W0GQR1XS
NCI-H28MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYPJR|UxRTlwMUC0Olkh|ryPMYHTRW5ITVJ?
ETK-1MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3zxT2lEPTB;OT6yPVk4PCEQvF2=MUjTRW5ITVJ?
NCI-H1993NHPL[4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIPJV5RKSzVyPUmuOFQzPjFizszNMWPTRW5ITVJ?
no-11NE\QSXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWXJR|UxRTlwNEexNkDPxE1?MnG2V2FPT0WU
ChaGo-K-1NEfKdpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWXUXnl4UUN3ME25MlUyPTh|IN88US=>Ml[zV2FPT0WU
NCCITMVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{HEVWlEPTB;OT61N|E3QSEQvF2=NX;nWVVqW0GQR1XS
SASMmnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXvJR|UxRTFyLkK0PEDPxE1?NYfsZ|BjW0GQR1XS
A673MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NU\LUGI3UUN3ME2xNE4{PzB2IN88US=>NWD2Z5pNW0GQR1XS
NCI-H1522Mnv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NU\m[VRIUUN3ME2xNE4{PzB5IN88US=>M3i3RnNCVkeHUh?=
NCI-H810NULKO4hWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYHFXo1rUUN3ME2xNE4{QTB5IN88US=>NXzsV2ltW0GQR1XS
IST-MES1M3LOZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV3ocYY3UUN3ME2xNE41PTZ2IN88US=>MV\TRW5ITVJ?
GR-STNUK3TnZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4TRdWlEPTB;MUCuOVAzPCEQvF2=Mn;lV2FPT0WU
SUP-T1NV[zS|VVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV7JR|UxRTFyLkezNVch|ryPM3\sOXNCVkeHUh?=
NB5MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlXxTWM2OD1zMD65NFIzKM7:TR?=NYSz[FVUW0GQR1XS
MZ1-PCMoSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmOwTWM2OD1zMD65OVcyKM7:TR?=MX;TRW5ITVJ?
SK-CO-1NXHub243T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFfCcGZKSzVyPUGwMlk6OzFizszNMVzTRW5ITVJ?
Capan-2NYHWUm9vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MofmTWM2OD1zMT6zNVk5KM7:TR?=MVnTRW5ITVJ?
697MlG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NU\W[JN3UUN3ME2xNU43PzV5IN88US=>NEWzTVVUSU6JRWK=
REHM1rVSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXnRTm05UUN3ME2xNU44PDVzIN88US=>M2XLOHNCVkeHUh?=
GI-1NH3UVHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnntTWM2OD1zMT64OlE2KM7:TR?=MkX2V2FPT0WU
BB65-RCCNGew[WJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mlf6TWM2OD1zMj6wPVE3KM7:TR?=NHXySnpUSU6JRWK=
NCI-H1651NXjhOlFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV7rcWw2UUN3ME2xNk4zPDd6IN88US=>M2TvbHNCVkeHUh?=
NCI-H1618NWi0Z3R7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml3HTWM2OD1zMj6zPVc3KM7:TR?=M2ewWHNCVkeHUh?=
NCI-H2081NYDXWIFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M13sSmlEPTB;MUKuOlE1OSEQvF2=NHLvXpFUSU6JRWK=
GCIYMl3vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{jOUWlEPTB;MUKuO|IyOyEQvF2=M3y2WHNCVkeHUh?=
NYM2HlSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml:2TWM2OD1zMz6wOlQ{KM7:TR?=M37v[HNCVkeHUh?=
PANC-03-27MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWjJR|UxRTF|LkC4NFch|ryPMl;QV2FPT0WU
BHYNYm0cmw2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUL4O2hxUUN3ME2xN{4zOTJzIN88US=>MmfwV2FPT0WU
SK-OV-3M{S4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkjYTWM2OD1zMz6zO|Y{KM7:TR?=MUXTRW5ITVJ?
5637NY\sU|NMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{\4dGlEPTB;MUOuO|c2QSEQvF2=NXzLU4xxW0GQR1XS
LC-1FMlP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHLGVJNKSzVyPUG0MlA{PTZizszNMYDTRW5ITVJ?
SNB75NFz3fJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHrJVlVKSzVyPUG0MlA{QDNizszNMo\HV2FPT0WU
CHP-212MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX3JR|UxRTF2LkC0OlQh|ryPM1X3SnNCVkeHUh?=
HT-1376Mmq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFPseW9KSzVyPUG0MlEyOjZizszNMXrTRW5ITVJ?
MONO-MAC-6M2HkNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHTl[HZKSzVyPUG0MlE2ODJizszNMUHTRW5ITVJ?
CA46NELIUpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVPJR|UxRTF2LkG4Nlch|ryPM3\sUHNCVkeHUh?=
SCC-15NV;hOllET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkfSTWM2OD1zND61OVg{KM7:TR?=MVzTRW5ITVJ?
ATN-1MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHS4eYZKSzVyPUG0MlY3OjdizszNNYPYXpp6W0GQR1XS
NCI-H2405M2nyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXPJR|UxRTF2LkixOVch|ryPNXP3dW5HW0GQR1XS
NCI-H716MmO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1;ZNGlEPTB;MUSuPFQ6OyEQvF2=MVjTRW5ITVJ?
SW620MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXixN3BQUUN3ME2xOE46ODF2IN88US=>MXXTRW5ITVJ?
NCI-H226MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHXXOXZKSzVyPUG0MlkxQDVizszNMYrTRW5ITVJ?
SW962MlL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2Dyd2lEPTB;MUSuPVQ{OiEQvF2=M3PaZnNCVkeHUh?=
KYSE-150NIrkN25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVf0RYhyUUN3ME2xOE46PTVizszNMXPTRW5ITVJ?
OCUB-MNFnqO|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVzJR|UxRTF2Lkm4PFMh|ryPMXnTRW5ITVJ?
ES7NWPkUnhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF3GTVNKSzVyPUG1MlA6QDRizszNNH:xNlBUSU6JRWK=
SW1463NHr0O49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWfkdVNHUUN3ME2xOU41OjJ|IN88US=>NYi4epFZW0GQR1XS
CAKI-1M2T1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M131SGlEPTB;MUWuOVM1PiEQvF2=MUHTRW5ITVJ?
MKN28MmDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mm\vTWM2OD1zNT61OFc6KM7:TR?=NYDMVmliW0GQR1XS
SW13NILj[JdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MofITWM2OD1zNT62NVgh|ryPMmLjV2FPT0WU
A3-KAWM1;mWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFjSSWdKSzVyPUG1Mlk3QTdizszNMX3TRW5ITVJ?
LU-65MnvDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlTUTWM2OD1zNT65O|Y5KM7:TR?=NIf2WZdUSU6JRWK=
Calu-1NX\kNpNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlnWTWM2OD1zNj6wN|Y5KM7:TR?=NYWy[|ZKW0GQR1XS
ST486NWTNR3FVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFjpVnlKSzVyPUG2MlA1OzFizszNNG\OfpJUSU6JRWK=
BB30-HNCMlO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFviOY5KSzVyPUG2MlEzPDZizszNNHvHVmRUSU6JRWK=
EGI-1M1\3O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV7JR|UxRTF4LkS0OkDPxE1?MmnqV2FPT0WU
SH-4M1XWSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUjJR|UxRTF4LkS3N|Eh|ryPNV\wW|E{W0GQR1XS
MN-60NUWyXoRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXLJR|UxRTF5LkKyPVch|ryPNHvJUVJUSU6JRWK=
MPP-89M1XkcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVjqd3ZpUUN3ME2xO{4zPDV7IN88US=>NGi0TWFUSU6JRWK=
A2780MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{LTb2lEPTB;MUeuOFE{QSEQvF2=NEXsNIJUSU6JRWK=
DaoyMVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NE\UXpJKSzVyPUG3MlQ3QTVizszNNWfmNnNoW0GQR1XS
NCI-H2126MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIjJeWVKSzVyPUG3MlQ4PzFizszNMoTjV2FPT0WU
NCI-H1563NGjXW49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGnKeIFKSzVyPUG3MlQ6OTdizszNNH3MeoNUSU6JRWK=
8-MG-BAMVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{TpSmlEPTB;MUeuOlY1QCEQvF2=MVzTRW5ITVJ?
786-0NWfDfW9tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUjJR|UxRTF5LkizOVMh|ryPMl7ZV2FPT0WU
AM-38MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUDkb4R7UUN3ME2xO{46OzB4IN88US=>NUD4TJB2W0GQR1XS
COLO-824M3XETGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUH0Uoc5UUN3ME2xPE41PDN4IN88US=>MnLsV2FPT0WU
SK-MEL-30NIDUWo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGH4VIZKSzVyPUG4MlUxQDJizszNM1P6cnNCVkeHUh?=
CESSMVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYrUSnNsUUN3ME2xPE44PjB7IN88US=>NHnkbWtUSU6JRWK=
BL-70MnLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MofLTWM2OD1zOD64NVU3KM7:TR?=NUDOcldpW0GQR1XS
NCI-H2170MlfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIjHZWJKSzVyPUG4MlkyPzlizszNMknaV2FPT0WU
HT-3M3Lp[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1Xo[mlEPTB;MUiuPVg{KM7:TR?=NYHKV5dpW0GQR1XS
BOKUMmn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWDJN4dOUUN3ME2xPU4xOzhzIN88US=>MkXOV2FPT0WU
HPAF-IINFnB[JRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlPlTWM2OD1zOT6zNFE2KM7:TR?=MYTTRW5ITVJ?
KGNMX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVnJR|UxRTF7LkS3OlUh|ryPM{fLXnNCVkeHUh?=
MC-CARNHjOTJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NY\U[GpGUUN3ME2xPU43OzF|IN88US=>MYDTRW5ITVJ?
BHT-101M1XHSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYPJR|UxRTF7Lke3O{DPxE1?M1\IcXNCVkeHUh?=
SW1783NVy5TndvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHzhXJdKSzVyPUG5Mlc5ODZizszNMnLjV2FPT0WU
KP-N-YNM1[x[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3\OdWlEPTB;MkCuNFI3OiEQvF2=NIfxdZJUSU6JRWK=
LU-165NY[xeoI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn3aTWM2OD1{MD61OVcyKM7:TR?=M1vOVXNCVkeHUh?=
GOTOMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWLJR|UxRTJyLk[0OVEh|ryPNE\3SJRUSU6JRWK=
EFM-19MlXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHPBWFhKSzVyPUKxMlA4OTZizszNMUTTRW5ITVJ?
CTV-1MmHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYnJR|UxRTJzLkGwOVQh|ryPMnPKV2FPT0WU
HELMnfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnfqTWM2OD1{MT60NlE3KM7:TR?=NEfpdXhUSU6JRWK=
SNU-C2BM3XtUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmC2TWM2OD1{MT60NlYh|ryPMYfTRW5ITVJ?
ECC4M{PQSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWjjW5RoUUN3ME2yNU44ODdizszNMXPTRW5ITVJ?
NEC8MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUjTdGFPUUN3ME2yNU45OzZ6IN88US=>NFzFeGtUSU6JRWK=
KMOE-2MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{LOSWlEPTB;MkGuPFkzOSEQvF2=NGj4blNUSU6JRWK=
NCI-H524MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWPGUplCUUN3ME2yNk4xQDB6IN88US=>NYP0WYl[W0GQR1XS
WSU-NHLNH7RT|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1;JeGlEPTB;MkKuNVU4PyEQvF2=MXfTRW5ITVJ?
SF126M3rNVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHjGWnBKSzVyPUKyMlI1PjlizszNNGm0S3ZUSU6JRWK=
HOP-92MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGPoSY5KSzVyPUKyMlMyPjdizszNNVTkd4JDW0GQR1XS
CTB-1MoL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3XoeWlEPTB;MkKuOFY4PyEQvF2=M3ywOXNCVkeHUh?=
KYSE-270M{DNXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXfJR|UxRTJ{LkmzOVch|ryPNVqwfVl7W0GQR1XS
SK-MEL-24MkXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1PLdWlEPTB;MkOuNVg4KM7:TR?=MWjTRW5ITVJ?
Calu-3NH31N3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnHSTWM2OD1{Mz6yNVI5KM7:TR?=MVjTRW5ITVJ?
GAMGM4LNemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHHqNotKSzVyPUKzMlI{PjdizszNMYDTRW5ITVJ?
SW1573NIfs[4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFvxW4RKSzVyPUKzMlc1OTVizszNNYn2b4tLW0GQR1XS
MHH-NB-11NXXxZY9[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2XWdmlEPTB;MkSuNFE6PCEQvF2=MVLTRW5ITVJ?
TK10MmOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlnwTWM2OD1{ND61NFE{KM7:TR?=MYDTRW5ITVJ?
LB373-MEL-DMlTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlGxTWM2OD1{ND62NFY1KM7:TR?=MoXtV2FPT0WU
KALS-1M4[1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnfUTWM2OD1{ND63N|I4KM7:TR?=NHTGVXNUSU6JRWK=
HUTU-80M1z2dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVXJR|UxRTJ3LkiwN|Ih|ryPMUTTRW5ITVJ?
HuP-T3NF\B[W9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkXoTWM2OD1{Nj6xOlc1KM7:TR?=MXjTRW5ITVJ?
OE19MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHflSoNKSzVyPUK2MlIyPTNizszNMX\TRW5ITVJ?
J82NGL2[3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWHJR|UxRTJ4LkK0O|Eh|ryPM32ybHNCVkeHUh?=
DU-4475MlLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYfJR|UxRTJ4LkO4NVkh|ryPMYTTRW5ITVJ?
DMS-53MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYfvRW5vUUN3ME2yOk42OTN6IN88US=>NXn1WYVrW0GQR1XS
COLO-741NGm4PIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIHF[IhKSzVyPUK2Mlg{PDRizszNMnvZV2FPT0WU
SW48MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYPJR|UxRTJ4Lki4NkDPxE1?NUfiOGZQW0GQR1XS
IGR-1MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVfJR|UxRTJ4LkmzN|Qh|ryPNHPKemVUSU6JRWK=
639-VMUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1TpSWlEPTB;MkeuNFI1PSEQvF2=NWHwPG5jW0GQR1XS
LK-2M371TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{ficWlEPTB;MkeuOFE1OSEQvF2=NELTZppUSU6JRWK=
NCI-H2347NVn0R4RKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFrFPHVKSzVyPUK3Mlk3QTlizszNNGe4U5JUSU6JRWK=
NCI-H2228MnnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYXJR|UxRTJ6LkC5NFUh|ryPNH\HbFhUSU6JRWK=
LS-123NXnBdYZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M17FZ2lEPTB;MkiuNVI3OiEQvF2=NHez[IpUSU6JRWK=
U031NFvwcXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1vZUWlEPTB;MkiuNlUzKM7:TR?=M4r6[nNCVkeHUh?=
NCI-H1792MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1LvZ2lEPTB;MkiuOFczOSEQvF2=NXLWZm1WW0GQR1XS
NCI-H2087NGruOZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWrIdJF5UUN3ME2yPE44PTV{IN88US=>NEP1bJBUSU6JRWK=
NCI-H2342M2XMXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn2zTWM2OD1{OT61NlA5KM7:TR?=MXLTRW5ITVJ?
SW626MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkHUTWM2OD1{OT63OVYh|ryPM3XJcHNCVkeHUh?=
LB2518-MELMVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUDJR|UxRTJ7LkixOUDPxE1?MYTTRW5ITVJ?
RXF393M3vnRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnzWTWM2OD1|MD6wPVUzKM7:TR?=MlLjV2FPT0WU
LC4-1M1SwOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX;JR|UxRTNyLkOwPVIh|ryPMV;TRW5ITVJ?
NCI-H1694NHn0XpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVTnXHRKUUN3ME2zNE43PjJ2IN88US=>M{DrNXNCVkeHUh?=
K5NGWxNppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3;mOmlEPTB;M{CuPVcxOiEQvF2=M4P1cnNCVkeHUh?=
HDLM-2M3XTWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH[zVVBKSzVyPUOwMlk4OjVizszNMnfSV2FPT0WU
BCPAPM{jPTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3;JOmlEPTB;M{GuPFM4QSEQvF2=NGj3UYZUSU6JRWK=
BC-3NV:xV3N5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NU[5WlJmUUN3ME2zNk4yPDB|IN88US=>MYLTRW5ITVJ?
LB996-RCCMnSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYnrfZRTUUN3ME2zNk4zOzV6IN88US=>M1XHV3NCVkeHUh?=
NCI-H2009NFP5W3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3uzZ2lEPTB;M{KuOFk5OSEQvF2=NXzMVoFbW0GQR1XS
HTC-C3M4LL[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGDSblVKSzVyPUOzMlc2OTlizszNNXHE[G45W0GQR1XS
LAMA-84NILqXoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmTaTWM2OD1|ND60OFA4KM7:TR?=M4S2b3NCVkeHUh?=
CCRF-CEMNED3NI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYnJR|UxRTN2LkW3NVUh|ryPM{ixe3NCVkeHUh?=
AN3-CANWX5co41T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoS2TWM2OD1|NT6wOVY5KM7:TR?=NFW4NVNUSU6JRWK=
NCI-H1734M1[5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX3JR|UxRTN3LkK1OlEh|ryPNHvCO3RUSU6JRWK=
Ca-SkiNInQc3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVnJR|UxRTN3LkSxNFEh|ryPMnjhV2FPT0WU
U-266M2ryUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml\3TWM2OD1|NT62NVE1KM7:TR?=M2LhfXNCVkeHUh?=
SBC-5MljNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGTnTIFKSzVyPUO1Mlc4QDFizszNNGXDUYdUSU6JRWK=
GT3TKBNUHHdIZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFfZWYVKSzVyPUO3MlEyPSEQvF2=MWHTRW5ITVJ?
MDA-MB-175-VIINGryc5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEf2e2VKSzVyPUO3MlIzPDhizszNMVTTRW5ITVJ?
PFSK-1NVTKXmhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWDFZ|lYUUN3ME2zO{4zPDN3IN88US=>MlP1V2FPT0WU
IMR-5NEDWepdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXTJR|UxRTN5LkK0PFch|ryPNUHjXFg1W0GQR1XS
DaudiM{jNOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVfJR|UxRTN5LkO1PVch|ryPM2LsfHNCVkeHUh?=
A498MlHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1TzVmlEPTB;M{euO|IyQCEQvF2=NVHWRlh1W0GQR1XS
SCC-4NVH2OWR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVPVcpE{UUN3ME2zO{44QDR|IN88US=>M{m1OHNCVkeHUh?=
COLO-680NM1Xye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVfURpRKUUN3ME2zPE4zQDh3IN88US=>Mof3V2FPT0WU
SK-MES-1M37SXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWDIOW9NUUN3ME2zPE4{OjF3IN88US=>NVraXFR4W0GQR1XS
SRNIjLNnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnSxTWM2OD1|OD61OFk2KM7:TR?=MWHTRW5ITVJ?
LNCaP-Clone-FGCMlrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGf1UohKSzVyPUO4MlU3OzdizszNMnvoV2FPT0WU
SK-HEP-1MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFLFXXVKSzVyPUO4Mlc5OjJizszNMlfVV2FPT0WU
BPH-1NHjYNXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYXWOG1DUUN3ME2zPE45OzJ7IN88US=>M1f1TnNCVkeHUh?=
NCI-H1755MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWTmZo9sUUN3ME2zPU42QDF5IN88US=>M1nCOHNCVkeHUh?=
LXF-289NGL2Xm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXnzSIFQUUN3ME2zPU45ODh2IN88US=>NV36NHNzW0GQR1XS
SW1088NULGOYw2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NETQcVRKSzVyPUSwMlIyODdizszNMlnTV2FPT0WU
MOLT-4MmjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFPhdXpKSzVyPUSwMlI6ODFizszNMn;NV2FPT0WU
AsPC-1M1u5Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF7aN2xKSzVyPUSwMlQ2QDNizszNMlrtV2FPT0WU
HOP-62MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUTJR|UxRTRyLk[1Olgh|ryPMXPTRW5ITVJ?
A172M13tbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NI\Dd5hKSzVyPUSwMlg2OTFizszNMVrTRW5ITVJ?
SN12CMom2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWjvU5M1UUN3ME20NE46Ozh3IN88US=>M4\PW3NCVkeHUh?=
MDA-MB-231MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEj4dJBKSzVyPUSwMlk5QThizszNMVjTRW5ITVJ?
RPMI-2650Mn3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVjZWINQUUN3ME20NU4yPTl|IN88US=>MV7TRW5ITVJ?
KYSE-140MlzIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWjpW41jUUN3ME20NU45OTJ|IN88US=>M4fSUHNCVkeHUh?=
KINGS-1MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml\DTWM2OD12Mj60Olk4KM7:TR?=MkjqV2FPT0WU
HSC-3NHe1eGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlrsTWM2OD12Mj62OlYyKM7:TR?=Ml;DV2FPT0WU
PC-14NHTxNJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHjHdFNKSzVyPUSzMlE5QDJizszNMkTyV2FPT0WU
COR-L105NXLjcnRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUPRPGs6UUN3ME20N{43PTB{IN88US=>M3rDXnNCVkeHUh?=
BE-13M2HSOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEPtXYpKSzVyPUS0MlI{PzFizszNNV3FPItpW0GQR1XS
NCI-H661NIPZTXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXjJR|UxRTR2LkK5OVgh|ryPMXHTRW5ITVJ?
IST-MEL1NXXUR4xWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1q5Z2lEPTB;NESuN|U6QSEQvF2=Ml3SV2FPT0WU
HCC1806Ml[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2\rcmlEPTB;NESuOVg4OyEQvF2=MVLTRW5ITVJ?
COLO-800Mm\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYPJR|UxRTR2Lki0OVMh|ryPM2mwOXNCVkeHUh?=
IST-SL2NFXnPYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mlz0TWM2OD12NT6xNlQ4KM7:TR?=NYWzcI9jW0GQR1XS
8305CMWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX\aZ2lxUUN3ME20OU4{ODlizszNM1LI[nNCVkeHUh?=
UACC-62M{\1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkjETWM2OD12Nj6yPFc2KM7:TR?=NVLXbFR3W0GQR1XS
COR-L23NUXp[|BpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIHEdJBKSzVyPUS3MlE6QSEQvF2=MYnTRW5ITVJ?
EFE-184MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4\qZ2lEPTB;NEeuN|g5KM7:TR?=MlHxV2FPT0WU
DMS-114M{XIVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnrwTWM2OD12Nz60NVQ6KM7:TR?=MVHTRW5ITVJ?
KYSE-520MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWX5eoNpUUN3ME20PE42OzF3IN88US=>NFfvUVhUSU6JRWK=
SNG-MM4LTS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2npXmlEPTB;NEmuOFM1KM7:TR?=NG\2NlVUSU6JRWK=
A2058NHPNd3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUfwRWt5UUN3ME20PU41QDh3IN88US=>NV[4[FlTW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the Vmax is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. [1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. [2]
Features

Protocol(Only for Reference)

Kinase Assay: [1]

Protein kinase biochemical assays Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log10 compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerProTM Kinase Selectivity Assay Kit.

Cell Assay: [1]

Cell lines MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells
Concentrations 0.02-0.8 μM
Incubation Time 3 days
Method For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only.

Animal Study: [1]

Animal Models IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model
Formulation 25 mM tartaric acid
Dosages 25 mg / kg and 75 mg / kg
Administration Orally administrated at once-daily oral dose for 14 days

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Mulvihill MJ, et al. Future Med Chem, 2009, 1(6), 1153-1171.

[2] McKinley ET, et al. Clin Cancer Res, 2011, 17(10), 3332-3340.

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-04-16)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02057380 Active, not recruiting Advanced Solid Tumors Astellas Pharma Global Development, Inc.|Astellas Pharma Inc April 2014 Phase 2
NCT02546544 Recruiting Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research a  ...more University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT01427205 Withdrawn Head and Neck Cancer M.D. Anderson Cancer Center|OSI Pharmaceuticals June 2013 Phase 2
NCT01567384 Withdrawn Cancer|Neoplasms|Tumors Emory University|OSI Pharmaceuticals May 2012 Phase 1
NCT01560260 Completed Carney Complex|Chondrosarcoma|Gastrointestinal Stromal Tumor|Paraganglioma National Cancer Institute (NCI) March 2012 Phase 2

view more

Chemical Information

Download OSI-906 (Linsitinib) SDF
Molecular Weight (MW) 421.49
Formula

C26H23N5O

CAS No. 867160-71-2
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 84 mg/mL (199.29 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 30% PEG400/0.5% Tween80/5% propylene glycol 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name (1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutanol

Customer Product Validation (3)


Click to enlarge
Rating
Source Cancer Res 2013 73, 834-843. OSI-906 (Linsitinib) purchased from Selleck
Method Cell proliferation and growth assays
Cell Lines PFR3 cells
Concentrations 1 μM
Incubation Time
Results The IC50 of PFR3 cells for PF299804 was more than 100 fold lower with the combination of OSI-90 than with PF00299804 alone.

Click to enlarge
Rating
Source Cancer Res 2011 71, 6773-84. OSI-906 (Linsitinib) purchased from Selleck
Method [18 F]FDG –PET/ Western blot
Cell Lines MCF-7 cells/athymic mice
Concentrations 50 mg/kg/day
Incubation Time 6 weeks
Results mice without palpable tumors were randomized to treatment with vehicle or OSI-906. Six of 20 control mice (30%) developed tumors, whereas none of the 20 OSI-906–treated mice did (Fig. A). OSI-906 inhibited tumor growth compared with vehicle (Fig. B; P < 0.05). OSI-906–treated tumors exhibited markedly lower levels of phosphorylated IGF-IR, InsR, IRS-1, AKT, and S6 compared with vehicle controls (Fig. C). FDG uptake was significantly decreased 4 hours after a single dose of OSI-906 com-pared with baseline (Fig. D)

Click to enlarge
Rating
Source OSI-906 (Linsitinib) purchased from Selleck
Method Flow cytometry/ Western Blotting
Cell Lines CLL B cells
Concentrations 1 µM
Incubation Time 24 h
Results three structurally unrelated IGF1R inhibi tors AG1024, Picropodophyllin (PPP) and linsitinib significantly reduced the cellular viability of primary CLL cells ( Figure A) and reduced levels of phosphorylated IGF1R and IRS-1 (Figure B,C). AG1024, which showed the strongest effect on viability, caused a dose-dependent decrease in the levels of phosphorylated Src, PI3K, Akt, MEK and ERK (Figure D).

Product Use Citation (15)

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related IGF-1R Products

  • Picropodophyllin (PPP)

    Picropodophyllin (PPP) is a selective IGF-1R inhibitor with IC50 of 1 nM. Phase 1/2.

  • Erlotinib

    Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • R428 (BGB324)

    R428 (BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).

  • BMS-536924

    BMS-536924 is an ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2.

  • NVP-AEW541

    NVP-AEW541 is a potent inhibitor of IGF-1R/InsR with IC50 of 150 nM/140 nM in cell-free assays, greater potency and selectivity for IGF-1R in a cell-based assay.

  • NVP-ADW742

    NVP-ADW742 is an IGF-1R inhibitor with IC50 of 0.17 μM, >16-fold more potent against IGF-1R than InsR; little activity to HER2, PDGFR, VEGFR-2, Bcr-Abl and c-Kit.

  • GSK1904529A

    GSK1904529A is a selective inhibitor of IGF-1R and IR with IC50 of 27 nM and 25 nM in cell-free assays, >100-fold more selective for IGF-1R/InsR than Akt1/2, Aurora A/B,B-Raf, CDK2, EGFR etc.

  • BMS-754807

    BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.

    Features:Muti-inhibitor of the IGR-1R/IR family.

  • AG-1024

    AG-1024 (Tyrphostin) inhibits IGF-1R autophosphorylation with IC50 of 7 μM, is less potent to IR with IC50 of 57 μM and specifically distinguishes between InsR and IGF-1R (as compared to other tyrphostins).

  • PQ 401

    PQ401 inhibits autophosphorylation of IGF-1R domain with IC50 of <1 μM.

Recently Viewed Items

Tags: buy OSI-906 (Linsitinib) | OSI-906 (Linsitinib) supplier | purchase OSI-906 (Linsitinib) | OSI-906 (Linsitinib) cost | OSI-906 (Linsitinib) manufacturer | order OSI-906 (Linsitinib) | OSI-906 (Linsitinib) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us